Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Rhea-AI Summary

Maze Therapeutics (NASDAQ: MAZE), a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for renal, metabolic and cardiovascular diseases, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. The company's CEO, Jason Coloma, Ph.D., will deliver a company overview presentation on Thursday, June 5, 2025 at 2 p.m. ET. Investors can access the live webcast through the Investors section of Maze's website at www.MazeTx.com, where it will remain archived for 60 days after the presentation.

News Market Reaction – MAZE

+6.01%

+6.01% Session move

In the trading session that priced this news, MAZE gained 6.01%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET.

A live webcast will be available in the Investors section of the company's website at www.MazeTx.com and archived for 60 days following the presentation.

About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which provides insights into the genetic variants in disease and links them with the biological pathways that drive disease in specific patient groups. The company’s pipeline is led by two wholly owned programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for patients. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com

FAQ

When is Maze Therapeutics (MAZE) presenting at the Jefferies 2025 Global Healthcare Conference?

Maze Therapeutics will present at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET.

Who will be presenting for Maze Therapeutics (MAZE) at the Jefferies Healthcare Conference?

Jason Coloma, Ph.D., Chief Executive Officer of Maze Therapeutics, will present the company overview.

How can investors access Maze Therapeutics' (MAZE) presentation at the Jefferies Conference?

Investors can access the live webcast through the Investors section of Maze's website at www.MazeTx.com, where it will be archived for 60 days.

What therapeutic areas does Maze Therapeutics (MAZE) focus on?

Maze Therapeutics focuses on developing small molecule precision medicines for renal, metabolic and cardiovascular diseases.